<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032508</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210094</org_study_id>
    <secondary_id>2021-002052-36</secondary_id>
    <nct_id>NCT05032508</nct_id>
  </id_info>
  <brief_title>Efficacy of the Application of Xylocaine Impregnated Compress in Reducing Per-procedural Pain During Ultrasound-guided Infiltration of Trigger Finger</brief_title>
  <acronym>SAUTYLO</acronym>
  <official_title>Efficacy of the Application of Xylocaine Impregnated Compress in Reducing Per-procedural Pain During Ultrasound-guided Infiltration of Trigger Finger: a Randomized, Double-blind Controlled Study (SAUTYLO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation de l'Avenir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Xylocaine impregnated compress in&#xD;
      reducing per-procedural pain during ultrasound-guided infiltration of Trigger Finger&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trigger finger ultrasound-guided infiltrations are frequent and painful invasive procedures.&#xD;
&#xD;
      However, there is no current recommendation for per-procedural pain management, and in the&#xD;
      majority of cases, infiltration is performed without prior skin anesthesia.&#xD;
&#xD;
      Xylocaine patches are of controversial efficacy in pain acute management. In current&#xD;
      practice, they are not prescribed in advance and they are not well adapted to the topography&#xD;
      of the finger.&#xD;
&#xD;
      On the other hand, a recent study showed the interest of administering lidocaine 2% by J-tip,&#xD;
      a needle-free injection technique not available in France, before infiltration of Trigger&#xD;
      Finger.&#xD;
&#xD;
      The investigators hypothesize that an impregnated compress in Xylocaine 20 mg/ml injectable&#xD;
      solution, applied 15 minutes before the procedure, would reduce per-procedural pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average pain intensity during the ultrasound-guided infiltration.</measure>
    <time_frame>Day 0, immadiately after infiltration</time_frame>
    <description>Evaluation assessed by self-administered pain numeric rating scale (0, no pain and 100, maximum pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 0</time_frame>
    <description>Adverse events based on a self-administered open-ended question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain acceptance level in patients with trigger finger during the ultrasound-guided infiltration</measure>
    <time_frame>Day 0</time_frame>
    <description>Pain acceptance will be assessed according to the patient himself on a self-administered scale (0, not at all acceptable and 100, completely acceptable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain acceptance level assessed by the operator during the ultrasound-guided infiltration of trigger finger</measure>
    <time_frame>Day 0</time_frame>
    <description>Pain acceptance will be assessed according to the operator, on a scale (0, not at all acceptable and 100, completely acceptable).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Trigger Finger</condition>
  <arm_group>
    <arm_group_label>xylocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaïne Aguettant 20 mg/ml</intervention_name>
    <description>Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.</description>
    <arm_group_label>xylocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0,9%</intervention_name>
    <description>Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years or older&#xD;
&#xD;
          -  Trigger Finger (clinically defined by painful difficulty or protrusion when extending&#xD;
             the finger) with an ultrasound-guided infiltration of cortisone derivatives&#xD;
             indication.&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Affiliation to a Social Security system&#xD;
&#xD;
          -  Prior medical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological conditions affecting the hand other than carpal tunnel syndrome&#xD;
&#xD;
          -  Intra-articular infiltration of the hand or the wrist ≤ 2 months&#xD;
&#xD;
          -  Allergy to Xylocaine&#xD;
&#xD;
          -  Contraindication to Xylocaine or cortisone derivatives&#xD;
&#xD;
          -  Cognitive or behavioral disorders that make assessment impossible&#xD;
&#xD;
          -  Persons referred to in articles L 1121-5; 6; 8; 9 of the Public Health Code (protected&#xD;
             adults, under guardianship or curatorship, etc)&#xD;
&#xD;
          -  Pregnancy and breastfeeding; absence of contraceptive method for women of childbearing&#xD;
             age&#xD;
&#xD;
          -  Participant unable to speak, read and write French&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri GUERINI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henri GUERINI, MD</last_name>
    <phone>+33 1 58 41 25 02</phone>
    <email>henri.guerini@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia PEAUDECERF, PhD</last_name>
    <phone>+33 1 58 41 12 13</phone>
    <email>laetitia.peaudecerf@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Henri GUERINI, MD</last_name>
      <phone>+33 1 58 41 25 02</phone>
      <email>henri.guerini@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christelle Nguyen, MD, PhD</last_name>
      <phone>+33 1 58 41 29 45</phone>
      <email>christelle.nguyen2@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trigger Finger</keyword>
  <keyword>Xylocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigger Finger Disorder</mesh_term>
    <mesh_term>Pain, Procedural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

